ElevateBio is a Waltham-based technology-driven company powering transformative cell and gene therapies for the biopharma industry. It begins with an environment where scientific inventors can transform their visions for cell and gene therapies into reality for patients with devastating and life-threatening diseases. Working with leading biopharma and academic partners, ElevateBio's team of scientists, drug developers, and company builders are building an integrated ecosystem that is changing the face of cell and gene therapy and regenerative medicine.
Stay up-to-date with news from across the ElevateBio ecosystem.
David Hallal, Chairman and CEO of ElevateBio, is a 30-year veteran in the biopharmaceutical industry, with expertise in early-stage company building as well as operating large multinational biotech companies.
Dr. Mitchell (Mitch) Finer, President of Research and Development at ElevateBio, has been instrumental in founding, building and leading a number of MPM portfolio companies. Mitch serves on several MPM portfolio company boards, including CODA, Oncorus, Semma Therapeutics and TCR2 Therapeutics.
Vikas Sinha, CFO of ElevateBio, has more than 25 years of experience in executive finance roles in the life sciences industry. He previously served as the CFO of Alexion Pharmaceuticals. During his tenure as CFO, Alexion’s market cap grew from $600 million to more than $30 billion and revenue grew from zero to more than $3 billion.
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.png)
.png)
